Compare FIEE & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FIEE | HOTH |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | 43 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 18.0M |
| IPO Year | N/A | 2019 |
| Metric | FIEE | HOTH |
|---|---|---|
| Price | $2.46 | $1.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | N/A | ★ 229.5K |
| Earning Date | N/A | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $0.66 |
| 52 Week High | N/A | $3.80 |
| Indicator | FIEE | HOTH |
|---|---|---|
| Relative Strength Index (RSI) | 54.24 | 50.43 |
| Support Level | $1.65 | $1.16 |
| Resistance Level | $2.59 | $1.27 |
| Average True Range (ATR) | 0.20 | 0.08 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 84.51 | 84.62 |
FiEE Inc, formerly Minim Inc is a digital service provider focused on integrating artificial intelligence and data analytics into content creation and brand management. The company offers a range of services designed to support creators, artists, and businesses in developing, managing, and optimizing their digital presence across various platforms, including customized graphic and posts, short videos, and editorial calendars aligned with brand goals.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).